MNAT1

Across TCGA pan-cancer cohorts, MNAT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MNAT1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MNAT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MNAT1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where MNAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.842	1.000	.002	59	view →
LUAD	DFS	Median	III,IV	0.995	0.485	.003	9	view →
UCEC	OS	Tertile	All	1.000	0.846	.018	8	view →
LSCC	DFS	Median	II,III,IV	0.844	0.565	.025	4	view →
GBM	DFS	Quartile	All	0.540	0.285	.044	2	view →
HNSC	OS	Median	III,IV	0.484	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MNAT1–CCRCC (DFS)

Open the CCRCC breakdown →